UCB stock pre-market at EUR 234.50: biopharma group starts the day
Published on 10/22/2026 at 08:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline timing and business model
- UCB develops and delivers medicines for severe neurological and autoimmune diseases.
- UCB lists topline results for STACCATO alprazolam in Q4 2026 or H1 2027.
- UCB stock trades pre-market at EUR 234.50 at 7:58 a.m. CEST at Lang & Schwarz on October 22, 2026.
UCB develops and delivers medicines for people living with severe neurological and autoimmune diseases, according to the company’s company profile. UCB stock trades pre-market at EUR 234.50 at 7:58 a.m. CEST at Lang & Schwarz on October 22, 2026.
Clinical pipeline timing
UCB’s investor-relations materials list topline results for the investigational STACCATO alprazolam program in Q4 2026 or H1 2027. The same materials describe UCB’s research focus as neurology and immunology and identify medicines including BIMZELX, FINTEPLA and RYSTIGGO. These details are reported by UCB Investor Relations.
Pre-market trading
The bid is EUR 227.50 and the ask is EUR 241.50, a 5.97 percent spread indicating thin pre-market trading. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of UCB stock.
Business and market context
UCB combines drug discovery, research, development and manufacturing with patient partnerships. Its investor-relations materials describe a portfolio focused on neurological and immunological diseases, while the company profile identifies Brussels as its headquarters. Market context: Market report Euro Stoxx 50.
